Backed by 20+ Medical trials
in clinical research
From recent clinical trial (1), NHS pilots (2), and over 30,000 real-world users (3), Flow has repeatedly been shown to support reducing depressive symptoms.
Results at 10 weeks from a multisite, double-blind placebo-controlled randomised superiority trial were statistically significant for both primary and secondary endpoints. Flow achieved a 57.5% remission rate using the MADRS scale and was effective as both standalone and adjunctive therapy.1
The EMPOWER clinical trial also showed Flow can have an enhanced effect when supplemented with an antidepressant. More research is needed to examine this further. This impact has also been reported in real-world cases.
Open-label patient cohort study in an NHS primary care general practice found at 6 weeks:
- 58.1% of patients showed reliable improvement, and 32.3% achieved remission using the PHQ-9
- Significant improvements were observed in functioning (WSAS) and health-related quality of life (EQ-5D-5L)
A 10-week review of 2,000+ Flow users revealed the overall composition of depression severity shifted dramatically over the 10-week period3. At the start, 20% of patients had severe depression, 65% were moderate, and 15% were mild. By Week 10, only 6% remained in the severe category, with 38% of all patients reaching remission—demonstrating Flow’s ability to significantly reduce symptom severity across all patient groups.
It is important to note the results reflect that patients with milder symptoms require a smaller point reduction to reach remission, while those with severe depression need more significant improvement to achieve the same result.
Everything you need to succeed with Flow
A short text about this section if needed. It’s not neccessary, but it’s available to make it more inviting and descriptive.
